Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Core Insights - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines to address unmet medical needs in Japan and globally [1][3]. Company Overview - Nxera Pharma has established a new-generation commercial business in Japan aimed at developing and commercializing innovative medicines for a large and growing market in the APAC region [2]. - The company employs approximately 400 professionals across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under the ticker 4565 [4]. Pipeline and Research - Nxera is advancing a pipeline of over 30 active programs from discovery to late clinical stages, utilizing its unique NxWave™ discovery platform [3]. - The pipeline focuses on addressing major unmet needs in rapidly growing medical fields such as neurology/neuropsychiatry, metabolic diseases, and immunology and inflammation [3]. Recent Developments - Neurocrine Biosciences presented new positive data from the Phase 2 study of NBI-1117568 for schizophrenia at the ASCP 2025 Annual Meeting, which is relevant to Nxera's interests in the neurology sector [1].